TPG Biotech
VC Fund
San Francisco, United States
TPG Biotech is a VC fund in San Francisco focused on Biotechnology and Health Care. TPG Biotech is part of the growth equity and venture investment platform of TPG, the global private investment firm. TPG Biotech targets investments in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, as well as industrial applications of biotechnology. TPG Biotechhas access to the broader resources of TPG.
- Total investments:
- 55
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries TPG Biotech invests in
Stages TPG Biotech invests in
Countries TPG Biotech invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Kelvin L. Davis
|
|||
Kevin Lind
|
|||
William S. Price
|
Investment Focus
Industry
- Biotechnology 26 (47%)
- Health Care 15 (27%)
- Medical 11 (20%)
- Pharmaceutical 10 (18%)
- Biopharma 8 (15%)
Stage
- Series B 16 (29%)
- Series A 11 (20%)
- Series C 11 (20%)
- Series D 7 (13%)
- Funding Round 2 (4%)
Country
- United States 25 (45%)
- Israel 2 (4%)
- Japan 1 (2%)
- Canada 1 (2%)
- Denmark 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Eran Nadav
Managing Director
|
Managing Director | Total investments: 9 | Find email | |
Jim Coulter
Co-Founder
|
Co-Founder | Total investments: 9 | Find email | |
|
Kelvin L. Davis
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
|
Kevin Lind
Lead Underwriter
|
Lead Underwriter | Total investments: 0 | Find email | |
|
William S. Price
Co-Founder
|
Co-Founder | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Achieve Life Science
|
Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M / Post-IPO Equity / Apr 16, 2026 | |
Avalyn Pharma
|
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novelinhaled therapeutics.Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington. | $100M / Series D / Jul 22, 2025 | |
ADCendo
|
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $135M / Series B / Nov 25, 2024 | |
Carisma Therapeutics
|
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $30M / Series C / Sep 21, 2022 | |
|
Carisma Therapeutics
|
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $12M / Series B / Mar 01, 2021 | |
|
Carisma Therapeutics
|
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $47M / Series B / Jan 07, 2021 | |
Azura Ophthalmics
|
Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S. | $20M / Series C / Oct 22, 2020 | |
DNAnexus
|
DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the worldthat are tackling some of the most challenging and exciting opportunities in human health.The company was founded in 2009 and is based in Mountain View, California. | $100M / Series G / Jun 09, 2020 | |
|
Avalyn Pharma
|
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novelinhaled therapeutics.Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington. | $35.5M / Series B / Apr 27, 2020 | |
Satsuma Pharmaceuticals
|
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasaldelivery device. | $62M / Series B / Apr 24, 2019 | |
| See all 55 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does TPG Biotech invest in?
TPG Biotech invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 55 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact TPG Biotech?
Public channels for TPG Biotech include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TPG Biotech?
The team at TPG Biotech includes Eran Nadav (Managing Director), Jim Coulter (Co-Founder) and Kelvin L. Davis (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
